Quantinno Capital Management LP Grows Position in GSK plc (NYSE:GSK)

Quantinno Capital Management LP boosted its holdings in shares of GSK plc (NYSE:GSK - Free Report) by 7.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 106,753 shares of the pharmaceutical company's stock after buying an additional 6,948 shares during the quarter. Quantinno Capital Management LP's holdings in GSK were worth $3,610,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Indiana Trust & Investment Management Co boosted its stake in shares of GSK by 200.0% during the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock worth $25,000 after acquiring an additional 500 shares during the last quarter. Crews Bank & Trust bought a new position in GSK in the 4th quarter worth $26,000. Sierra Ocean LLC bought a new position in GSK in the 4th quarter worth $32,000. Parkside Financial Bank & Trust lifted its position in GSK by 470.1% during the fourth quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock valued at $34,000 after purchasing an additional 818 shares in the last quarter. Finally, Golden State Wealth Management LLC bought a new stake in GSK during the fourth quarter valued at about $38,000. 15.74% of the stock is currently owned by institutional investors.

GSK Price Performance

Shares of GSK traded up $0.37 during mid-day trading on Thursday, hitting $38.91. 5,844,691 shares of the stock were exchanged, compared to its average volume of 4,839,871. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The company has a market cap of $80.28 billion, a PE ratio of 24.47, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.80. The firm has a 50-day moving average of $37.33 and a two-hundred day moving average of $36.00.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. The business had revenue of $10.06 billion for the quarter, compared to the consensus estimate of $7.52 billion. GSK had a return on equity of 48.59% and a net margin of 8.13%. The company's quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.43 earnings per share. On average, equities analysts predict that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be issued a dividend of $0.4216 per share. This represents a $1.69 annualized dividend and a yield of 4.33%. The ex-dividend date is Friday, May 16th. This is a positive change from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio is presently 86.60%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on GSK. Hsbc Global Res upgraded GSK to a "strong sell" rating in a research report on Monday, April 28th. Wall Street Zen raised shares of GSK from a "buy" rating to a "strong-buy" rating in a report on Thursday, April 24th. Morgan Stanley began coverage on shares of GSK in a research note on Wednesday, February 12th. They set an "equal weight" rating on the stock. Finally, BNP Paribas initiated coverage on shares of GSK in a report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price target on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and four have issued a strong buy rating to the company's stock. According to data from MarketBeat, GSK presently has a consensus rating of "Moderate Buy" and a consensus price target of $40.58.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.